|
| Home : RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement |
|
Apr 07
2016 |
RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement |
|
VANCOUVER, BRITISH COLUMBIA--(Marketwired - April 6, 2016) - RepliCel Life Sciences Inc. ("RepliCel" or the "Company") (OTCQB:REPCF) (TSX VENTURE:RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that its Board of Directors has authorized a plan to downsize all non-critical programs and staff in an effort to preserve capital to focus on the following three essential priorities pending a major financing or corporate transaction: (1) continued protection of intellectual property, (2) assembling of data from the RCT-01 and RCS-01 clinical trials expected near year-end 2016, and (3) the completion of a licensing/co-development transaction related to one of the four products the Company has in development (the "Critical Interim Priorities"). |
|
|
|
| Source:http://www.marketwired.com/mw/release.do?id=2112374&sourceType=3 |
| |
|
Related News
|
» Duos Technologies Group Closes $1.8 Million Senior Secured Non-Convertible Note Financing
» Kaizen Discovery Receives C$2.0 Million from Majority Shareholder HPX TechCo as a Partial Drawdown of Loan Facility
|
|
|
